arsenic has been researched along with Myelomonocytic Leukemia, Chronic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Canesastraro, M; Di Raimondo, F; Galimberti, S; Nagy, B; Palumbo, G; Petrini, M; Savlı, H; Sünnetçi, D | 1 |
1 other study(ies) available for arsenic and Myelomonocytic Leukemia, Chronic
| Article | Year |
|---|---|
Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bortezomib; Cell Cycle Checkpoints; Cell Line, Tumor; Disease Progression; Drug Synergism; Estradiol; Gene Expression Regulation, Leukemic; Gene Regulatory Networks; Humans; Leukemia, Myelomonocytic, Chronic; Neoplasm Proteins; NF-kappa B; Oxides; Proteasome Inhibitors; Signal Transduction | 2015 |